Form 4: RxSight Director Julie Andrews Sells Shares Under 10b5-1 Trading Plan

Julie Andrews, a director at RxSight, Inc., executed sales of common stock on June 14, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On June 14, 2024, Julie Andrews, a director of RxSight, Inc., sold shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on March 12, 2024.
• A total of 11,940 shares were sold at a weighted average price of $57.8399, within a price range of $57.32 to $58.29.
• An additional 3,685 shares were sold at a weighted average price of $58.5291, within a price range of $58.32 to $59.03.
• Following these transactions, Ms. Andrews still beneficially owns 30,287 shares of RxSight common stock.
• A power of attorney was executed on June 13, 2024, granting certain individuals the authority to act on Ms. Andrews' behalf in matters related to SEC filings.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating stock sales by a company director under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transactions.

Industry Context

Sales by company directors are a normal part of business, but are closely watched by investors. The fact that these sales were executed under a pre-arranged 10b5-1 trading plan suggests that the sales were planned well in advance and not based on any recent inside information.

Stakeholder Impact

• The stock sales may have a minor impact on shareholders, potentially causing a slight decrease in stock price due to increased supply.
• The sales do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates